- Home
- ENLV vs ANL Comparison
ENLV vs ANL Comparison
Compare ENLV & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENLV | ANL |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | Israel | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 293.4M |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ENLV | ANL |
|---|---|---|
| Price | $1.10 | $6.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $13.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 209.2K | 197.2K |
| Earning Date | 04-29-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.88 |
| 52 Week High | $2.10 | $12.09 |
Technical Indicators
Market Signals| Indicator | ENLV | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 49.86 | 37.92 |
| Support Level | $1.00 | $1.36 |
| Resistance Level | $1.23 | $9.98 |
| Average True Range (ATR) | 0.06 | 0.83 |
| MACD | -0.01 | -0.31 |
| Stochastic Oscillator | 45.45 | 10.91 |
Price Performance
Historical ComparisonAbout ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.